Physician profile
Ruben Aleman
NPI 1447227608
$4,047.39
in general payments reported to CMS, 2019-2025
26 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,000 · 2020: $195 · 2021: $461 · 2022: $455 · 2023: $375 · 2024: $357 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,873.75 | 2019-2024 | |
| Novo Nordisk INC | $295.29 | 2020-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $290.71 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.78 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.03 | 2021-2024 | Jardiance |
| Organon LLC | $118.93 | 2022-2025 | Nexplanon |
| Abbott Laboratories | $113.85 | 2019-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $113.27 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $111.95 | 2019-2021 | |
| Exact Sciences Corporation | $89.07 | 2023-2025 | Cologuard Collection Kit |
| Cumberland Pharmaceuticals, INC. | $65.58 | 2019-2023 | Kristalose |
| Amgen INC. | $62.35 | 2019-2022 | |
| Abbvie INC. | $51.93 | 2021-2023 | Viberzi, Linzess |
| Genentech USA, INC. | $50.97 | 2019-2021 | |
| Allergan, INC. | $48.68 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $40.47 | 2025 | Flucelvax, Fluad |
| Takeda Pharmaceuticals U.S.A., INC. | $38.79 | 2022 | |
| Inspire Medical Systems, INC. | $31.48 | 2025 | Inspire |
| Hologic Sales and Service, LLC | $27.00 | 2024 | Aptima |
| Evofem Biosciences, INC. | $23.62 | 2022 | |
| Mannkind Corporation | $21.43 | 2020 | |
| Dexcom, INC. | $18.40 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $17.49 | 2021 | |
| Shire North American Group INC | $15.65 | 2019 | |
| Horizon Therapeutics Plc | $10.92 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Aleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.